This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
这位英伟达分析师以看好的态度开始覆盖; 这是周二的前5个启动
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
华尔街顶级分析师改变了对这些顶级公司的展望。如需查看包括升级和降级在内的所有分析师评级变化的完整视图,请参阅我们的分析师评级页面。
- Redburn Atlantic analyst Timm Schulze-Melander initiated coverage on NVIDIA Corporation (NASDAQ:NVDA) with a Buy rating and announced a price target of $178. Nvidia shares closed at $145.26 on Monday. See how other analysts view this stock.
- Benchmark analyst Matthew Harrigan initiated coverage on VEON Ltd. (NASDAQ:VEON) with a Buy rating and announced a price target of $48. VEON shares closed at $33.17 on Monday. See how other analysts view this stock.
- UBS analyst Eliana Merle initiated coverage on Altimmune, Inc. (NASDAQ:ALT) with a Buy rating and announced a price target of $26. Altimmune shares closed at $7.35 on Monday. See how other analysts view this stock.
- Capital One analyst Dan Guglielmo initiated coverage on FrontView REIT, Inc. (NYSE:FVR) with an Overweight rating and announced a price target of $22. FrontView REIT shares closed at $18.97 on Monday. See how other analysts view this stock.
- UBS analyst Eliana Merle initiated coverage on Sagimet Biosciences Inc. (NASDAQ:SGMT) with a Buy rating and announced a price target of $12. Sagimet Biosciences shares closed at $5.85 on Monday. See how other analysts view this stock.
- Redburn Atlantic的分析师Timm Schulze-Melander对英伟达公司(纳斯达克:NVDA)进行了覆盖,给出了买入评级,并宣布目标价为178美元。英伟达的股票在周一收于145.26美元。看看其他分析师如何看待这只股票。
- Benchmark的分析师Matthew Harrigan对veon ltd(纳斯达克:VEON)进行了覆盖,给出了买入评级,并宣布目标价为48美元。veon ltd股票在周一收于33.17美元。看看其他分析师如何看待这只股票。
- 瑞银分析师Eliana Merle对altimmune, Inc.(纳斯达克:ALT)进行了覆盖,给出了买入评级,并宣布目标价为26美元。altimmune股票在周一收于7.35美元。看看其他分析师如何看待这只股票。
- Capital One的分析师Dan Guglielmo对FrontView REIt, Inc.(纽交所:FVR)进行了覆盖,给出了超配评级,并宣布目标价为22美元。FrontView REIt股票在周一收于18.97美元。看看其他分析师如何看待这只股票。
- 瑞银分析师Eliana Merle对Sagimet Biosciences Inc.(纳斯达克:SGMT)进行了覆盖,给出了买入评级,并宣布目标价为12美元。Sagimet Biosciences股票在周一收于5.85美元。看看其他分析师如何看待这只股票。
Considering buying NVDA stock? Here's what analysts think:
考虑买入NVDA股票吗?以下是分析师的看法:
Read More:
阅读更多:
- Jim Cramer: This Tech Stock Can 'Go To 160,' Recommends Buying Domino's Pizza
- 吉姆克雷默:这家科技股票可以'涨到160美元',建议购买达美乐披萨